Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with rio...

Повний опис

Збережено в:
Бібліографічні деталі
Автори: Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias Lange, Karen M. Olsson, Hans Klose, Ekkehard Grünig
Формат: Artigo
Мова:Англійська
Опубліковано: 2018
Онлайн доступ:https://doi.org/10.1186/s12931-018-0957-y
https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-018-0957-y
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Інтернет

https://doi.org/10.1186/s12931-018-0957-y
https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-018-0957-y

Схожі ресурси